United Therapeutics (UTHR)
(Delayed Data from NSDQ)
$342.59 USD
-2.43 (-0.70%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $342.56 -0.03 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$342.59 USD
-2.43 (-0.70%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $342.56 -0.03 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth B Momentum C VGM
Zacks News
Earnings Preview: United Therapeutics (UTHR) Q1 Earnings Expected to Decline
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
United Therapeutics (UTHR) Down 13% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is iShares US SmallCap Equity Fac (SMLF) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SMLF
Should iShares MSCI USA Small-Cap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SMMV
Should iShares MSCI USA Small-Cap Multifactor ETF (SMLF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SMLF
United Therapeutics (UTHR) Q4 Earnings & Sales Miss Estimates
by Zacks Equity Research
United Therapeutics' (UTHR) fourth-quarter earnings and sales miss estimates. Tyvaso sales continue to drive the company's top line.
United Therapeutics (UTHR) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of -35.19% and 0.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy United Therapeutics (UTHR) Ahead of Earnings?
by Zacks Equity Research
United Therapeutics (UTHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Strength Seen in Liquidia Technologies, Inc. (LQDA): Can Its 9.7% Jump Turn into More Strength?
by Zacks Equity Research
Liquidia Technologies, Inc. (LQDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
UTHR vs. ZTS: Which Stock Is the Better Value Option?
by Zacks Equity Research
UTHR vs. ZTS: Which Stock Is the Better Value Option?
After Plunging -5.18% in 4 Weeks, Here's Why the Trend Might Reverse for United Therapeutics (UTHR)
by Zacks Equity Research
United Therapeutics (UTHR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Why You Should Hold Molina Healthcare (MOH) in Your Portfolio
by Zacks Equity Research
Molina Healthcare (MOH) remains well-poised for growth on the back of a growing customer base within its Government business. Acquisitions and cost-saving measures also aid the health insurer.
Should iShares S&P MidCap 400 Growth ETF (IJK) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IJK
Encompass Health's (EHC) Plan Marks Entry in Rhode Island
by Zacks Equity Research
Encompass Health (EHC) aims to build a 50-bed inpatient rehabilitation hospital in Rhode Island and extend its advanced rehabilitative services suite across the Northeast.
Is iShares MSCI USA SmallCap Multifactor ETF (SMLF) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for SMLF
UTHR or ESALY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UTHR vs. ESALY: Which Stock Is the Better Value Option?
Centene (CNC) Wins Contract From DHCS to Serve Medi-Cal Members
by Zacks Equity Research
Centene's (CNC) California subsidiary receives a contract from the DHCS to better address the health requirements of the state's Medi-Cal members.
Best Momentum Stock to Buy for January 4th
by Zacks Equity Research
UTHR and AXON made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 4, 2023.
New Strong Buy Stocks for January 4th
by Zacks Equity Research
STAA, CASY, THRM, MP and UTHR have been added to the Zacks Rank #1 (Strong Buy) List on January 4 , 2023.
Should iShares MSCI USA SmallCap Min Vol Factor ETF (SMMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SMMV
Should iShares MSCI USA SmallCap Multifactor ETF (SMLF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SMLF
The Zacks Analyst Blog Highlights United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly
by Zacks Equity Research
United Therapeutics, Intra-Cellular Therapies, Immunocore Holdings and Eli Lilly are part of the Zacks top Analyst Blog.
3 Drug Stocks Most Wall Street Analysts Are Bullish About
by Ekta Bagri
Here we present three drug and biotech stocks, UTHR, ITCI and IMCR, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2023 despite an uncertain macro environment.